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SUMMARY
The pathways by which oncogenes, such as MLL-AF9, initiate transformation and leukemia in humans and
mice are incompletely defined. In a study of target cells and oncogene dosage, we found that Mll-AF9,
when under endogenous regulatory control, efficiently transformed LSK (LinSca1+c-kit+) stem cells, while
committed granulocyte-monocyte progenitors (GMPs) were transformation resistant and did not cause
leukemia. Mll-AF9 was expressed at higher levels in hematopoietic stem (HSC) than GMP cells. Mll-AF9
gene dosage effects were directly shown in experiments where GMPs were efficiently transformed by the
high dosage ofMll-AF9 resulting from retroviral transduction.Mll-AF9 upregulated expression of 192 genes
in both LSK and progenitor cells, but to higher levels in LSKs than in committed myeloid progenitors.INTRODUCTION
Cellular development proceeds in a hierarchical fashion from
rare self-renewing stem cells to committed progenitor (transit-
amplifying) cells to differentiated postmitotic cells (Jordan
et al., 2006). Currently, little is known as to whether naturally
occurring cancers arise from normal stem cells or from commit-
ted progenitor cells, either of which could potentially acquire
oncogenic mutations.
Research on translocations involving MLL fusion oncogenes
has been extremely productive for more than 20 years and has
revealed important information about the biology of leukemia in-
cluding the role of HOX gene expression, histone modifications,
and leukemia stem cells (Krivtsov and Armstrong, 2007). The
well-studied MLL-AF9 oncogene initiates myeloid leukemia in
both humans and mice (Dobson et al., 1999; Iida et al., 1993).
An Mll-AF9 transgenic murine model that results in myeloid leu-
kemia has been described and studied in some detail (Corral432 Cancer Cell 13, 432–440, May 2008 ª2008 Elsevier Inc.et al., 1996; Johnson et al., 2003; Kumar et al., 2004). In this
model, the Mll-AF9 oncogene, introduced by homologous re-
combination, is under control of the endogenous Mll promoter
and, thus, expressed at physiologic levels. This model is poten-
tially informative because it permits the study of well character-
ized mammalian hematopoietic stem and progenitor cells
(Akashi et al., 2000; Spangrude et al., 1988).
A study of the MLL-ENL fusion gene introduced by retrovirus
showed that both hematopoietic stem cells (HSCs) and commit-
ted myeloid progenitor cells were transformed by the fusion
oncogene with highest efficiency in HSC population (Cozzio
et al., 2003). More recent studies showed that MLL-AF9 intro-
duced by retrovirus could transform both early hematopoietic
progenitors (Somervaille and Cleary, 2006) and committed mye-
loid progenitors (Krivtsov et al., 2006). A potential limiting factor in
these previous studies comes from the utilization of retroviruses
to introduce the oncogene. Retroviral introduction can result in
noncontrolled and potentially nonphysiologic levels of oncogeneSIGNIFICANCE
In a comparison ofMll-AF9 oncogene expression in retroviral and knockinmodels, we showed a direct relationship between
transformation susceptibility and oncogene dosage in committed progenitor cells. In the knockin model where oncogene
expression is under endogenous regulatory control, we found high Mll-AF9 gene expression levels and high expression
levels of downstream target genes in stem compared to committed progenitor cells. These results encourage further anal-
ysis of physiologically regulated oncogene dosage effects on genes that are critical to cell-specific transformation suscep-
tibility. Studies of cell-specific effects are increasingly important with the recognition that certain oncogenes, such as the
MLL fusion genes, are globally active.
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Stem Cell Transformation by the Mll-AF9 Oncogeneexpression, depending on the numbers of viral integrations and
the type of promoters. The transforming effects of cellular onco-
genes, includingMLL fusions,MYC,BCR-ABL, andCEBPA, may
differ significantly depending on oncogene expression levels
(Caslini et al., 2004; Chapiro et al., 2006; Ren, 2004). To circum-
vent these limitations, we studied the knockin Mll-AF9 murine
model, which permits a direct comparison of the susceptibility
to transformation of LSK (Linc-kit+Sca-1+, including hematopoi-
etic stem cell HSC and common lymphoid progenitor CLP) stem
and committed myeloid progenitor (common myeloid progenitor
CMP and granulocyte-monocyte progenitor GMP) cells. The
knockin model also permits expression ofMll-AF9 at physiologic
gene dosages, which we postulate should differ across the
hematopoietic stem and various progenitor cells populations
based on studies of wild-type Mll expression (Jude et al., 2007;
McMahon et al., 2007).
We report differences in transformable cells (LSKs > CMPs >
GMPs) when the MLL fusion oncogene is expressed at physio-
logic gene doses. We describe the importance of oncogene
dosage which is suggested by (1) differences in Mll-AF9
expression in HSCs and GMPs and (2) biologic differences
between retrovirally introduced MLL-AF9 and endogenous
Mll-AF9 expression.
RESULTS
Mll-AF9 Mice Show Increased HSCs, CLPs, and CMPs
Bonemarrow cells from 8- to 10-week-oldMll-AF9 knockin mice
or theirwild-type (WT) siblingswere used in this study. At this age,
Mll-AF9mice show myeloid cell proliferation but do not develop
leukemia until 6 months of age (Chen et al., 2006; Corral et al.,
1996). We sorted bone marrow cells into previously well-defined
progenitor or stem cell populations. LinSca1+c-kit+ (LSK) (Ikuta
andWeissman, 1992; Spangrude et al., 1988)markerswere used
to sort the closely related self-renewal hematopoietic stem cells
(HSCs) and common lymphoid progenitors (CLPs) (Kondo
et al., 1997; So et al., 2003; Terskikh et al., 2003). The comparison
groups of committedmyeloid progenitors included commonmy-
eloid progenitors (CMPs) andgranulocyte-monocyte progenitors
(GMPs). Analysis of the sorting profiles of HSCs, CLPs, CMPs,
and GMPs revealed that Mll-AF9 resulted in increased percent-
ages of c-kit+Sca1+ cells in both the HSC and CLP populations
(Figure 1A). We also saw an increased number of FcgRII/IIIlo
(CMP) but not FcgRII/IIIhi (GMP) cells. In multiple experiments,
sorted cell populations fromMll-AF9mice showed a consistently
higher percentageofHSCs,CLPs, andCMPs, but notGMPs (Fig-
ure 1B), when compared to the ones from WT mice (Figure 1B).
Leukemia Risk Is Dependent on the Type of
Transplanted Cells that Express Physiologic
Levels of Mll-AF9
MLL-ENL, when introduced into stem and progenitor cell popu-
lations (including HSCs, CMPs, and GMPs) by retrovirus and
under the control of the retroviral promoter, transformed those
populations and produced leukemia in transplanted mice with
additional events (Cozzio et al., 2003). Similarly, retrovirally
transduced MLL-AF9 transformed GMP cells and produced
leukemia (Krivtsov et al., 2006). In this study, we tested the ability
of Mll-AF9, expressed under the control of the endogenous Mllpromoter, to transform stem and progenitor cell populations
and to produce leukemia in transplanted mice.
Lethally irradiated WT mice received 25–2500 sorted Mll-AF9
HSC, CLP, CMP, or GMP cells. Results are shown in Figure 2A
and with more details in Table 1. A hierarchy in the ability to pro-
duce leukemia was found: The progeny of only 100 HSCs were
sufficient to produce fatal leukemia in 90% of animals. However,
only the higher dose of 2500 (but not 250) CMPs caused disease
and with a longer latency than the recipients of LSKs (p < 0.0001,
log-rank test). The relatively long latency to leukemia even with
LSKs (HSCs/CLPs) suggests that additional events are required
to develop fatal leukemia. In repeated experiments, none of the
animals receiving GMPs developed leukemia even at the maxi-
mum of 2500 GMP cells. To determine the minimum number of
Figure 1. Mll-AF9 Results in the Expansion of HSC, CLP, and CMP
Populations
(A) Sorting profiles of HSCs, CLPs, CMPs, and GMPs showing the expansion
of c-kit+Sca1+ HSCs (in LinIL-7R population) and CLP (in LinIL-7R+ popu-
lation) in Mll-AF9 mice. Expansion of the CMP population is also shown.
(B) Significantly higher percentages of HSCs, CLPs, and CMPs were found in
lineage negative marrow cells of Mll-AF9 than those of wild-type mice. Error
bars represent the standard error of the means.Cancer Cell 13, 432–440, May 2008 ª2008 Elsevier Inc. 433
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HSCs each, two of which developed leukemia (Table 1). By limit-
ing dilution analysis, the frequency of ‘‘transformable hematopoi-
etic cells’’ (THCs) was 1:45 in HSCs and 1:57 in CLPs, which was
significantly higher than the1:1043 inCMPs (p<0.0001) (Table 1).
Although the different cell populations exhibited varying ability
to cause disease, the type of leukemia caused by those cells was
similar. Immunophenotyping revealed that the majority of cells
from the enlarged spleens of recipient animals were myeloid
(CD11b+Gr1+) in phenotype (Figure 2B). Leukemias could be
transferred to secondary recipients and the immunophenotype
remained the same as the transplanted cells from the primary re-
cipients (data not shown). The demonstration that the relatively
mature ‘‘downstream’’ myeloid leukemia cells are independent
of the cell types transplanted is similar to that reported in the
retroviral MLL-ENL and MLL-AF9 models (Cozzio et al., 2003;
Somervaille and Cleary, 2006).
Mll-AF9-Induced Transformation Is Highest in Stem
Cells and Lowest in GMPs in Mll-AF9 Knockin Mice
In a series of experiments, we studied themechanisms for thedif-
ferences in leukemia outcomes based on the critical cell types.
Figure 2. HSCs and CLPs Are More Efficient than CMPs and GMPs
in Producing Leukemia In Vivo
(A) Survival of irradiated mice receiving 100–2500 cells. The survival rate was
calculated using Kaplan-Meier analysis. The HSC and CLP groups had signifi-
cantlypoorer survival than theCMPandGMPgroups (p<0.0001, log-rank test).
(B) Recipient mice developedmyeloid leukemia after transplantation. All recip-
ient mice showed the same high CD11b+Gr1+ profile in spleen previously
described in Mll-AF9 leukemic mice. FACS on the spleen of a representative
recipient is shown on the right while the isotype control is shown on the left.434 Cancer Cell 13, 432–440, May 2008 ª2008 Elsevier Inc.We first compared the self-renewal effects of Mll-AF9 knockin
stem and progenitor cells using a myeloid colony forming assay
(Johnson et al., 2003). Sorted cells were cultured in methylcellu-
lose medium containing IL-3, IL-6, SCF, and GM-CSF, replated
every 7 days, and colonies were studied at day 21. Figure 3A
shows the significant increase in colony numbers from all
Mll-AF9 stem/progenitor cells compared to wild-type. Notably,
LSKs formed the greatest number of colonies, with CMPs and
GMPs forming significantly fewer colonies. We and others have
previously shown that in addition to increased colony numbers,
MLL fusion genes induce the formation of compact colonies,
which are composed predominantly of immature myeloid cells
(Johnson et al., 2003; Somervaille and Cleary, 2006). As shown
in Figure 3B, significantly more compact colonies were found in
Mll-AF9 LSK cultures than in those fromCMP and GMP cultures.
No compact colonies were found in anywild-type cultures. Over-
all, colony assays showed that enhanced self-renewal induced
byMll-AF9 was greatest in LSKs (HSCs/CLPs) compared to the
committed myeloid progenitor populations (CMPs and GMPs).
Immunophenotyping revealed that cells from colonies in all
Mll-AF9 groups were CD11b+Gr1+/ myeloid (Figure S1).
Retrovirus-Induced Expression ofMll-AF9
in GMPs Results in Increased Myeloid Colonies
and Long-Term Self-Renewal In Vitro; These Changes
Are Not Found in Mll-AF9 Knockin GMPs
In contrast to the GMPs transformed by knockinMll-AF9 that did
not produce leukemia, GMPs transformedby theMLL-AF9 retro-
virus were capable of producing leukemia in transplanted ani-
mals (Krivtsov et al., 2006). Thus, we compared the effects of
MLL-AF9 in GMPs transduced by retrovirus to those in GMPs
from Mll-AF9 knockin mice. Wild-type GMPs were transduced
with MSCV-MLL-AF9-GFP retrovirus as previously described
(Krivtsov et al., 2006), while Mll-AF9 knockin GMPs were trans-
duced with the MSCV-GFP retrovirus as controls. The reagents
and protocols for these studies were identical to those used by
Krivtsov et al. In the first series of experiments, we compared
myeloid colonies from both methods of fusion gene introduction.
GFP+ cells were selected as previously described and myeloid
colonies were counted after three sequential platings on day
21. Results in Figure 3C, left panel, show that total myeloid col-
onies were more than four times higher in the GMPs transduced
by MLL-AF9 retrovirus than in Mll-AF9 knockin GMPs trans-
duced with the MSCV-GFP control virus. Similarly, when colony
types were examined, more compact immature colonies were
found in theMLL-AF9 transduced cells than in the knockin cells
that constitutively express Mll-AF9 (Figure 3C, right panel).
These data show enhanced self-renewal ofMLL-AF9 retrovirally
transformed cells in vitro; enhanced self-renewal of these cells
was further shown in cytokine (IL-3, IL-6, SCF, andGM-CSF)-en-
riched liquid culture whereMll-AF9 knockin cells did not survive
beyond 20 days, while retroviral MLL-AF9 cells continued to
grow in long-term liquid culture (Figure S2).
MLL-AF9 Expression Is Significantly Higher
in Retrovirally Transduced GMPs Than
in Mll-AF9 Knockin GMPs
The known strength of the retroviral promoter, combined with
data from the colony assays and Southern blotting, all suggested
Cancer Cell
Stem Cell Transformation by the Mll-AF9 OncogeneTable 1. Summary Data of Transplantation Experiments
Starting Mll-AF9
Population
No. of Cells
Transplanted
No. of Animals
Transplanted
No. of Animals
with AML (%)
Latency of AML (Median
and 95% CI in Days)
Frequency of Transformable
Hematopoietic Cells (THCs)
HSC 25 5 2 (40%) -a (167, -) 1:45
100 10 9 (90%) 165 (152, 197)
CLP 100 5 4 (80%) 198 (134, NA) 1:57
250 5 5 (100%) 136 (119, 179)
2500 5 5 (100%) 137 (131, 199)
CMP 250 5 0 (0%) - (-, -) 1:1043
2500 5 5 (100%) 181 (138, 210)
GMP 250 5 0 (0%) - (-, -) –
2500 6 0 (0%) - (-, -)
Five negative control mice injected with 2.5 3 105 WT bone marrow cells were all alive for the duration of the experiment.
a Inestimable.that expression of MLL-AF9 will be higher in retrovirally trans-
duced GMPs than in Mll-AF9 knockin GMPs. Using primers
that detected a sequence present in both retroviral MLL-AF9
and knockin Mll-AF9 constructs (but not in wild-type mice), we
compared the expression levels of the fusion gene in the
MLL-AF9 transduced GMPs to those in MSCV-GFP transduced
Mll-AF9 GMPs by real-time quantitative RT-PCR. Figure 3D, left
panel, shows that GFP+ MLL-AF9 retrovirally transduced cells
had 170-fold higher expression of MLL-AF9 than knockin
GMPs with virus control. In long term culture, expression levels
of MLL-AF9 in the subclones from MLL-AF9 retrovirally trans-
duced GMPs remained very high (Figure 3D, right panel). Results
from Southern blotting with GFP as a probe on the genomic DNA
from these cultured cells showed more than one band; these
results provide evidence that multiple MLL-AF9 integrations
were likely (Figure S3).
Gene Expression Profiles Induced by Mll-AF9
Expressed at Physiologic Levels
A goal of our study was to define the molecular pathways that
would explain the differences between Mll-AF9 HSCs and
GMPs. We compared the early (preleukemic) in vivo effects of
the Mll-AF9 fusion gene on gene expression levels in the cells
from Mll-AF9 knockin mice. RNA was extracted from sorted
HSCs, CLPs, CMPs, and GMPs and amplified for analysis by
Affymetrixmurine4302.0microarrays. To identify genesdifferen-
tially expressed as a result ofMll-AF9 expression, we performed
a two-way ANOVA using a stratified permutation test (See
Supplemental Experimental Procedures). Allowing for a false
discovery rate (FDR) of 10% (Benjamini and Hochberg, 1995),
this analysis yielded 446 genes that were differentially expressed
inMll-AF9 compared toWTcells (Figure S4). A clustering analysis
was performed using this 446 gene set, with results shown in
Figure 4A. The expected clustering of CMPs with GMPs and
HSCs with CLPs was found.Mll-AF9 HSCs and CLPs were clus-
tered with each other instead of their wild-type counterparts,
suggesting very similar downstream effects of the fusion gene
in the two related populations. Of the 446 genes selected by
the two-way ANOVA, 192 were expressed at high levels in all
four Mll-AF9 cell types compared to wild-type, while 179 genes
displayed lower expression in the Mll-AF9 populations (Tables
S1 and S2). The top 50 genes upregulated in all four cell typesare shown in the heat map in Figure 4B. These genes are ranked
in decreasing order of fold changes in HSCs.
Further analysis of the 192 upregulated genes in the Mll-AF9
populations revealed 96 genes more highly expressed in trans-
formation-sensitive LSKs compared to transformation-resistant
CMPs/GMPs (FDR < 0.1, Significance Analysis of Microarrays;
Tusher et al., 2001). The top 50 of the 96 Mll-AF9 LSK overex-
pressedgenes are shown in the heatmapofMll-AF9 transformed
cells in Figure 5A. Representatives of the genes more highly ex-
pressed in LSK than in CMP/GMP group are well-known targets
of Mll and Mll-fusion proteins—Hoxa5, Hoxa9, and Meis1. Also
included is Evi1, not currently known to be a direct target of Mll
orMll fusion genes. Evi1 overexpressionwas confirmed by quan-
titative RT-PCR shown in Figure S5. We analyzed in more detail
the relative levels of known targets Hox5, Hoxa9, Meis1, and
Evi1 in each population of cells with results shown in Figure 5B.
Importantly, these four genes were most highly expressed in
Mll-AF9 LSKs, expressed at intermediate levels in wild-type
LSKs and Mll-AF9 CMPs/GMPs, and expressed at the lowest
levels in wild-type CMP/GMPs. Several of the 192 genes that
we found to be upregulated byMll-AF9 in all four cell populations,
including Hoxa5, Hoxa9, Hoxa10, and Meis1, were previously
found to be highly ‘‘immediately’’ expressed in GMP cells trans-
formed by theMLL-AF9 retrovirus (Krivtsov et al., 2006).
We also carried out a comparative analysis of the previously
reported leukemias resulting from retrovirus transduced GMPs
(Krivtsov et al., 2006) and our knockin preleukemia cells. This
analysis showed 20 genes that were upregulated in both groups
(Table S3). Included were the expected Hoxa5, Hoxa7, Hoxa9,
Hoxa10, andMeis1 genes plus novel genes, such as IL31 recep-
tor A and Chemokine-like factor super family 6 genes. Since the
previous study used only GMPs rather than the four cell types of
this study and a different Affymetrix probe set, a complete com-
parison of the two is difficult, and it is likely that the number of
genes in common is actually greater than 20.
Expression of Mll and Mll-AF9 Is Higher
in HSCs Than in GMPs
We next evaluated the hypothesis that the upregulated expres-
sion of genes known to be downstream of Mll, such as Hoxa
genes in HSCs, could be a result of higher expression levels of
the Mll-AF9 fusion gene in HSCs. The expression of wild-typeCancer Cell 13, 432–440, May 2008 ª2008 Elsevier Inc. 435
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mature progenitors (Jude et al., 2007). Since the Mll-AF9 fusion
gene is present in all cells of knockin mice, we studied expres-
sion levels of the oncogene in the various hematopoietic cells
with the expectation that expression of Mll-AF9 would parallel
that of Mll. The microarray results showed that the expression
level of Mll was higher in WT than Mll-AF9 cells and was higher
in HSCs than GMPs (Figure 6A). Quantitative real-time RT-PCR
interrogating the 30 end of Mll showed that Mll expression level
in HSCs is 4- to 5-fold higher than in GMPs from Mll-AF9 mice
(Figure 6B). Similarly, using a 50 Mll primer/probe set, higher
expression was found in HSCs compared to GMPs (data not
shown). Quantitative real-time RT-PCR analysis was also per-
formed to evaluate Mll-AF9 levels in HSCs and GMPs. Results
Figure 3. In Mll-AF9 Knockin Mice, HSCs and CLPs Produce More
Total and Compact Myeloid Colonies with Enhanced Self-Renewal
In Vitro Than CMPs and GMPs, and MLL-AF9 Retrovirally Trans-
ducedGMPsProduce theMost Total andCompactMyeloidColonies
(A) Total myeloid colony numbers were higher in HSCs and CLPs than in CMPs
and GMPs in Mll-AF9 mice after 21 day culture under myeloid conditions. All
theMll-AF9 populations had significantly increased colonies compared toWT.
(B) Compact colony numbers were higher in HSCs/CLPs than in CMPs/GMPs
in Mll-AF9 mice after 21 day culture. No compact colonies were detected in
WT mice. Error bars represent standard error of the means.
(C) Total myeloid colony and compact colony numbers were the highest in
MLL-AF9 retrovirally transduced GMP cells compared to the MIG (MSCV-
IRES-GFP) vector transduced knockin Mll-AF9 GMPs and other knockin
Mll-AF9 GMP controls as labeled.
(D)MLL-AF9 expression in retrovirally transduced GMPs and knockinMll-AF9
GMPs. Error bars represent standard error of the means.436 Cancer Cell 13, 432–440, May 2008 ª2008 Elsevier Inc.in Figure 6C show 4- to 5-fold higher levels of Mll-AF9 in HSCs
compared to GMPs.
To summarize, the higher expression levels ofMll-AF9 in HSCs
compared to GMPs in the physiologic model suggests the
importance of Mll-AF9 gene dosage in producing downstream
effects in the Hoxa family and other genes, although other cell
context-specific differences are also likely to be important and
deserve further research.
DISCUSSION
This study focused on the malignant transformation initiated by
the fusion gene Mll-AF9 when expressed at physiologic levels
in the knockinmodel or at supraphysiologic levels in the retroviral
model. The data from the physiologic model showed highest
levels of Mll and Mll-AF9 in the most transformable HSCs and
lower levels in the more resistant committed myeloid progenitor
GMPs. Complementary data showed highMll-AF9 gene dosage
Figure 4. Hierarchical Clustering of Mll-AF9 HSCs/CLPs and
CMP/GMP Populations, and Genes Overexpressed in HSC, CLP,
CMP, and GMP Populations
(A) A two-way ANOVA with stratified permutation testing was performed to
select genes differentially expressed in Mll-AF9 compared to wild-type cells
in each of the four populations. Hierarchical clustering performed with the
446 genes selected by the two-way ANOVA (FDR < 0.1) separates the
HSCs/CLPs from the CMPs/GMPs. WT, wild-type; Mll, Mll-AF9.
(B)Mll-AF9 upregulates expression of genes in multiple cell types (FDR < 0.1,
two-way ANOVA with permutation testing). Heat-maps show the expression
level of the top 50 genes upregulated in the Mll-AF9 samples compared
to WT ranked in decreasing order of fold change upregulation in HSCs. Ex-
pression levels are represented by colors: black = median; red > median;
green < median. Gene identifiers are at right.
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enhanced self-renewal and ability to grow in long-term in vitro
culture. While it is possible that the cell-type differences in trans-
formation are unrelated to the expression levels of Mll-AF9 at
physiologic dosages, we favor the hypothesis that the ‘‘superac-
tivation’’ of target genes observed in HSCs/CLPs (LSKs) is likely
to be oncogene dose related. In support of the role ofMll fusion
gene expression in the different cell types are recent data with
conditional knockout mice: Wild-type Mll showed highest
expression in HSCs compared to other cell types (Jude et al.,
2007). Wild-type MLL and likely MLL fusion proteins bind to
Figure 5. A Set of Genes Are Upregulated by Mll-AF9 to Highest
Levels in HSCs/CLPs Compared to Both to Mll-AF9 CMPs/GMPs
and to Wild-Type HSCs/CLPs
(A) Mll-AF9 upregulated genes are highly expressed in HSCs and CLPs com-
pared to CMPs and GMPs. Of the 192 genes overexpressed in Mll-AF9 cells,
96 genes are expressed at higher levels in HSCs and CLPs compared to CMPs
and GMPs (FDR < 0.1, SAM). The top 50 genes in this subset are shown.
Expression levels are represented by colors: black = median; red > median;
green < median.
(B) Expression ofMll-AF9 upregulated genesHoxa5,Hoxa9,Meis1, and Evi1 is
highest inMll-AF9 HSCs/CLPs. Data represent average expression relative to
levels in wild-type GMPs.the promoters of many genes and serve as global regulators.
As a result, a large number of downstream target genes are
altered in regulation (Guenther et al., 2005; Milne et al., 2005;
Scacheri et al., 2006). These cell-type differences in expression
of Mll target genes appear to be further enhanced by Mll fusion
genes, resulting in activation of cellular pathways, especially
those that enhance self-renewal and block cellular differentia-
tion. However, it is possible that additional molecular differences
could result in increased sensitivity of HSCs to the fusion onco-
gene is possible. A combination of higher Mll-AF9 gene dosage
and a more receptive cellular environment may be responsible
for the superior transformation of LSKs.
Previously published studies with Mll fusion genes (MLL-ENL
or MLL-AF9) have utilized retroviruses with strong promoters
and multiple virus insertions resulting in noncontrolled and
potentially nonphysiologic expression levels of oncogene. Non-
physiologic expression could mask important cell-type-specific
effects on the promoters of target cells. One advantage of the
Mll fusiongene knockinmodel over retroviral or physicalmethods
is that the oncogene should be expressed at physiologic levels
with cell-type specificity. In the current study, the lackof leukemia
in lethally irradiated recipients of Mll-AF9 GMPs contrasts with
Figure 6. Mll-AF9 Expression Is Higher in HSC than GMP
Populations, and Retrovirally Transduced MLL-AF9 Results in Very
High Expression Levels of the Oncogene
(A) Mll expression in the HSCs and GMPs from WT and Mll-AF9 mice by
microarray.
(B) Mll expression in the HSCs and GMPs from Mll-AF9 mice by real-time
RT-PCR.
(C)Mll-AF9 expression in the HSCs and GMPs fromMll-AF9mice by real-time
RT-PCR.
Error bars represent standard error of the means.Cancer Cell 13, 432–440, May 2008 ª2008 Elsevier Inc. 437
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by retroviral transduction (Krivtsov et al., 2006). These results are
supported by our in vitro data which showed significantly en-
hanced cell growth in retrovirally transformed MLL-AF9 cells,
but not in physiologically expressed Mll-AF9 cells. Enhanced
self-renewal of retrovirally transformed GMPs was shown in the
ability of these cells to grow in long term culture in vitro. In previ-
ous results from a MLL-ENL model, leukemia developed in ani-
mals that received 800–2490 retrovirally transducedGMPs (Coz-
zio et al., 2003). Also, a shorter latency to leukemia development
is found in the retroviral models compared to our knockin model
(Cozzio et al., 2003; Krivtsov et al., 2006; Somervaille and Cleary,
2006). We cannot rule out the possibility that the more rapid de-
velopment of leukemia in retroviral models may in part or totally
be due to retroviral enhancement of secondary cooperating
events, but our short term myeloid colony data strongly suggest
that some differences are immediate and very direct. Also, it is
possible that the differences could result from the use of human
MLL in the retroviral construct compared to the endogenousmu-
rineMll in our studies. However, this is unlikely, as to date no dif-
ferences in critical domains have been described for human and
murineMLL, and theAF9 portion of bothmodels is identical. With
these caveats, it is likely that the differences between the retrovi-
ral MLL-AF9 and knockin Mll-AF9 experiments are due to gene
dosage effects. This conclusion is also supported by (1) the pres-
ence of multiple integration sites in the retrovirally transduced
cells shown by Southern blotting and (2) the strongMSCV-based
retroviral promoter in this study and others (Krivtsov et al., 2006;
Somervaille and Cleary, 2006).
Our results showing that knockinMll-AF9HSCsandCLPs, rep-
resenting the relatively undifferentiated LSK (Linc-kit+Sca-1+)
hematopoietic cells, are most efficiently transformed and are
similar to those reported for retrovirally introduced MLL-ENL
(Cozzio et al., 2003). Also, similar to the retroviralMLL-ENLmodel
and MLL-AF9 model (Somervaille and Cleary, 2006), the bulk of
cells of all the leukemias were relatively mature myeloid
CD11b+Gr1+ in type, irrespective of the phenotype of the trans-
planted transformedcells.However,wedidnotdetermine thena-
ture of the leukemia stem cells (LSCs) that initiate and maintain
the leukemia in the animal. The long latency for development of
the leukemias in animals suggests that there are important
genetic and/or epigenetic events occurring during this latency
period. These later events could also be important in determining
the phenotype of the LSCs. The results presented have
implications for therapy of both the early and later stages of
leukemia.
In our knockin model, 192 genes were found to be upregulated
by Mll-AF9 in all four cell populations. Several, including Hoxa3,
Hoxa5, Hoxa7, Hoxa9, Hoxa10, and Meis1, were previously
found to be highly ‘‘immediately’’ expressed in GMP cells trans-
formed by theMLL-AF9 retrovirus (Krivtsov et al., 2006). Also, as
discussed in the Results, we found 20 genes in common in our
knockin preleukemia data set and the leukemia data set de-
scribed earlier (Krivtsov et al., 2006). Another report showed
that MLL-AF9 introduced by retrovirus resulted in upregulation
of several critical genes when leukemia stem cells (LSCs) were
compared to the transformed preleukemic ‘‘initiating’’ cells
(Somervaille and Cleary, 2006). That study did not compare
gene signatures in wild-type compared to ‘‘initiating’’ cells.438 Cancer Cell 13, 432–440, May 2008 ª2008 Elsevier Inc.We found very high expression of Evi1 in Mll-AF9 cells com-
pared to the correspondingwild-type cells. High levels of expres-
sionofEvi1, havebeen reported in humanmyeloid leukemiaswith
MLL-rearrangements (Barjesteh van Waalwijk van Doorn-Khos-
rovani et al., 2003; Valk et al., 2004). Also, Evi1 overexpression
is sufficient to immortalize murine hematopoietic cells (Du et al.,
2005), which suggest that this gene should be studied further
for its role in the pathogenesis ofMLL-fusion leukemias.
The knockin murine Mll-AF9 model is useful because the
fusion gene is present and expressed in all progenitor and
stem cells. The situation in humans is less clear, since the cell
in which the humanMLL-AF9-producing translocation develops
is not defined. However, the humanMLL-AF9 gene will be pres-
ent both in the cells with the initial ‘‘hit’’ plus all progenitor cells
and cells at later stages of differentiation. While it is possible
that the transforming human MLL-AF9 translocation may take
place at a maturation stage later than the HSC, murine studies
suggest that this is much less likely to be functionally meaningful
than a ‘‘hit’’ within the HSC population. Future studies will be
necessary to further define this issue.
In conclusion, our results directly show that supraphysiologic
oncogene doses of Mll-AF9 produced biologically different
effects from physiologic doses in the same cell type. We also
show an association between oncogene dosage and cell type-
specific transformation susceptibility; however, the oncogene
dosage differences are less in the physiologic model compared
to the retroviral model. While we favor the hypothesis that both
Mll-AF9 expression differences between cells types and other
cell context differences are pathophysiologically important, di-
rect evidence will need to be provided in future studies. Seminal
earlier studies with myc and other oncogenes have shown that
gene dosage effects are central to the pathophysiology of
cancers that develop under natural conditions (Ren, 2004).
Experimental studies that introduce oncogenes by viruses
and other physical methods have been extremely important in
cancer biology research. However, to the extent that they result
in nonphysiologic oncogene expression levels, experimental
results may differ from those in naturally occurring cancers.
EXPERIMENTAL PROCEDURES
Mice
The Mll-AF9 mice were originally produced in the laboratory of Dr. Terence
Rabbitts (Leeds, UK). Briefly, heterozygous mice were produced by fusing
the human AF9 short form (breakpoint to 30 end) into exon 8 of the mouse
Mll gene (Corral et al., 1996) and have been maintained on a C57BL/6 back-
ground. The wild-type mice used in the experiments were the littermates of
Mll-AF9 mice. All the mice were housed under specific pathogen-free condi-
tions in an accredited facility at the University of Minnesota. All experiments
were conducted after approval by the Institutional Animal Care and Use
Committee (IACUC).
Cell Sorting and FACS Analysis
Single cell suspensions of bonemarrow were obtained from 8-week-oldWT or
Mll-AF9 mice. The purification of HSC population (LinThy1.1loSca-1+c-kit+)
was similar to the method described before (Kondo et al., 1997; Terskikh
et al., 2003). Briefly, bonemarrow cells were stained with biotin-conjugated lin-
eage specific anti-IL-7R (PharMingen, San Diego, CA) and cocktail antibodies
from the Lineage Cell Depletion Kit (Miltenyi, Bergisch Gladback, Germany)
according to manufacturer’s instructions. Lin+ cells were partially removed
by magnetic beads (MACS, Miltenyi, Bergisch Gladback, Germany). The re-
maining cells were stained with Streptavidin-PE-Cy5 conjugate and further
Cancer Cell
Stem Cell Transformation by the Mll-AF9 Oncogenestained with APC-conjugated anti-c-kit, FITC-conjugated anti-Sca-1, and
PE-conjugated anti-Thy1.1 antibodies (PharMingen, San Diego, CA). The
HSC population was sorted by FACSAria (BD Biosciences Immunocytometry
Systems, San Jose, CA).
The CLPs were sorted as LinIL-7R+Thy1.1Sca-1 loc-kit lo (Kondo et al.,
1997; So et al., 2003) using a similar method. CMPs (LinIL-7RSca-1
c-kit+CD34+FcgRII/IIIlo) and GMPs (LinIL-7RSca-1c-kit+CD34+FcgRII/IIIhi)
were separated as described previously (Manz et al., 2001; Terskikh et al.,
2003). The purity of sorted cell populations was >95% by postsort analysis.
Relative percentage of HSCs, CLPs, CMPs, and GMPs from lineage nega-
tive marrow cells in wild-type andMll-AF9marrow (Figure 1a, 1b) were calcu-
lated as follows: % HSCs is the percentage of Sca1+c-kit+Thy1lo cells in
LinIL-7R population; % CLPs is the percentage of Sca1+c-kit + cells in
LinThy1IL-7R+ population; % CMPs is the percentage of CD34+ FcgRII/IIIlo
cells in LinSca1c-kit + population; and% GMPs is the percentage of CD34+
FcgRII/IIIhi cells in LinSca1c-kit + population. Statistical comparisons were
performed using the two-tailed t test.
For FACS analysis, single cell suspensions from either cultured cells or
mouse hematopoietic organs (bone marrow or spleen) were stained with
FITC or PE-labeled anti-mouse antibodies, CD11b and Gr1 (PharMingen or
eBioscience, San Diego, CA), and acquired on a BD FACScalibur with Cell
Quest software. Data were analyzed with FloJo software (Tree Star Inc., San
Carlos, CA).
Methylcellulose Culture
Sorted cells were cultured in methylcellulose medium under myeloid condi-
tions, using methocult 3534 (StemCell Technologies, Vancouver, Canada)
and supplemented with 10 ng/ml GM-CSF (R&D, Minneapolis, MN) (Chen
et al., 2006). Cells were cultured in triplicate for 21 days with transfers every
7 days. Colonies containing over 50 cells were counted and classified under
the microscope as previously described (Jordan et al., 2006).
Mouse Transplantation with Sorted Cell Populations
Each sorted population was transplanted into mice at various doses: 25 and
100 sorted HSCs; 100, 250, and 2500 CLPs; and 250 and 2500 CMPs or
GMPs from Mll-AF9 were mixed with a radioprotective dose of 2.5 3 105
bone marrow cells from WT mice and injected into lethally irradiated
(960 rad) recipients. Each group contained at least five mice. Five recipient
mice injectedwith 2.53 105WTbonemarrow cells were used as negative con-
trols. Mice were sacrificed when they became detectably ill. Necropsy, FACS,
immunohistochemistry, and histopathology evaluations were performed at the
time of sacrifice. The survival rate was calculated using the Kaplan-Meier
method. The frequency of transformable hematopoietic cells was calculated
by limiting dilution analyses using L-calc software (StemCell Technologies).
Retrovirus Transduction
Retrovirus constructs MSCV-MLL-AF9-GFP, MSCV-GFP, and package plas-
mid psi-Eco were used to produce retrovirus supernatant by cotransfection of
293T cells. Transduction of WT orMll-AF9GMPs was performed as previously
described (Krivtsov et al., 2006). After transduction, GFP-positive cells were
sorted and put in methylcellulose culture for colony assays. RNA from these
cells was extracted to detect MLL-AF9 expression by quantitative RT-PCR.
DNA was purified and digested by EcoRI for Southern blotting.
Gene Expression Studies
For quantitative real-time RT-PCR, reverse transcription was performed using
the Supercript II reverse transcription kit (Invitrogen) and real-time PCR detec-
tion was performed using TaqMan primer/probe sets (Applied Biosystems
Inc., Foster City, CA) and an ABI 7500 Real-Time PCR system. For MLL-
AF9, real-time PCR detection was performed using SYBR Green. In all
RT-PCR experiments, Gapdh was used as the housekeeping gene. Changes
in expression calculations were performed by the 2DDCT method using the
Relative Expression Software Tool (REST, www.gene-quantification.info).
Microarray Analysis
For gene expression profiling, total RNA was extracted from sorted cells and
amplified (Affymetrix). Labeled cRNA was hybridized to Mouse 430 2.0 geno-
mic arrays. Normalization and analysis of chip data were performed using theExpressionist package (GeneData Inc., Supplemental Experimental Proce-
dures). Heat maps were generated using Cluster and Treeview http://rana.
lbl.gov/EisenSoftware.htm. See the Supplemental Data for detailedmicroarray
analysis.
ACCESSION NUMBERS
All microarray data have been deposited in NCBI’s Gene Expression Omnibus
(GEO; http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO
Series accession number GSE10627.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, five
supplemental figures, and three supplemental tables and can be found with
this article online at http://www.cancercell.org/cgi/content/full/13/5/432/
DC1/.
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